Patents Assigned to Merrimack Phamaceuticals, Inc.
  • PREDICTING TUMOR RESPONSES TO ANTIBODIES AGAINST HEPATOCYTE GROWTH FACTOR (HGF) AND/OR ITS COGNATE RECEPTOR, C-MET
    Publication number: 20170306415
    Abstract: The present invention provides methods for selecting a therapy for, or for providing a treatment to, a patient having a cancer. The methods of the present invention comprise detecting the protein biomarkers c-Met, HGF, and EpCAM in cancer cells or cancerous tissues of a subject, and predicting the subject's responsiveness to treatment with a c-Met-targeted or other HGF-inhibitory treatment, thereby enabling the selection and administration of an effective therapeutic.
    Type: Application
    Filed: October 1, 2015
    Publication date: October 26, 2017
    Applicant: Merrimack Phamaceuticals, Inc.
    Inventors: Adnan ABU-YOUSIF, Aaron FULGHAM, Brian HARMS, Gavin MACBEATH, Victoria RIMKUNAS